The Post-Humira Pivot: How AbbVie Reinvented Itself in 24 Months

In 2023, AbbVie faced the largest patent cliff in pharmaceutical history when Humira lost U.S. exclusivity — a drug that generated peak sales of over $21 billion annually. This module unpacks how AbbVie engineered a faster-than-expected recovery through Skyrizi and Rinvoq, why the story matters in interviews, and what it reveals about how AbbVie evaluates candidates' strategic thinking and resilience under pressure.